GlassScriptPhysician profile
Meredith L Orseth
NPI 1598178568
$11,739.77
in general payments reported to CMS, 2019-2025
31 companies · $3,330 in 2025
The $3,330 reported for 2025 was more than what 93% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $147 · 2021: $987 · 2022: $1,466 · 2023: $1,967 · 2024: $3,420 · 2025: $3,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,711 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,711.10 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,714.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,228.07 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,153.43 | 2019-2025 | |
| Leo Pharma INC. | $1,021.13 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $794.76 | 2019-2025 | Tremfya |
| Ucb, INC. | $788.77 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $691.20 | 2021-2025 | |
| Galderma Laboratories, L.P. | $562.41 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $534.92 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $455.25 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $443.49 | 2019-2025 | Siliq, Cabtreo, Arazlo |
| Lilly USA, LLC | $353.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Botanix Sb INC | $262.88 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $262.27 | 2024-2025 | Zoryve |
| Pfizer INC. | $228.97 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $204.37 | 2019-2024 | |
| Dermavant Sciences, INC. | $198.54 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $194.36 | 2019-2025 | Ilumya, Winlevi |
| Kerecis Limited | $116.16 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Amgen INC. | $114.57 | 2020-2025 | Otezla |
| Organon LLC | $85.38 | 2025 | Vtama |
| Almirall LLC | $81.53 | 2021-2025 | Klisyri, Seysara |
| Convatec INC. | $47.91 | 2025 | |
| Journey Medical Corporation | $39.33 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $35.46 | 2021-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $31.86 | 2019 | |
| Bausch Health US, LLC | $22.02 | 2024 | Targretin |
| Dermira, INC. | $19.08 | 2020 | |
| Smith+Nephew, INC. | $18.95 | 2024 | Grafix Pl |
| Helsinn Therapeutics (U.S.), INC. | $18.63 | 2023 | Valchlor |
| Mimedx Group, INC. | $15.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Orseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.